Beth Allen
Plus aucun poste en cours
Profil
Beth Allen is Chief Operating Officer of CeeTox, Inc. She is a Co-Owner of Proteomic Research Service, Inc. Previously, she worked at Genomic Solutions, Inc. in September 2000.
Dr. Allen received a PhD from Texas A&M University in 1997.
Anciens postes connus de Beth Allen
| Sociétés | Poste | Fin |
|---|---|---|
NextGen Sciences, Inc.
 NextGen Sciences, Inc. BiotechnologyHealth Technology NextGen Sciences, Inc. specializes in the identification and characterization of proteins. The company is based in Ann Arbor, MI. NextGen Sciences was acquired by NextGen Group Plc on November 05, 2006 for $1.70 million. | Corporate Officer/Principal | - |
Genomic Solutions, Inc.
 Genomic Solutions, Inc. Packaged SoftwareTechnology Services Genomic Solutions, Inc. designs, develops genomic and proteomic instrumentation software solutions. It provides cell based assays, gene expression analysis, array hybridization, drug discovery and assay assembly. The company was founded by Jeffrey S. Williams in 1997 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - |
Lab Pathways, Inc.
 Lab Pathways, Inc. Miscellaneous Commercial ServicesCommercial Services Lab Pathways, Inc. was founded in July of 2003 as a Contract Research Organization focused on in vitro toxicity screening of potential drug candidates and chemicals. CeeTox resides in 4,200-square-feet of state-of-the-art laboratory space in the Southwest Michigan Innovation Center (SMIC), a $13 million facility that serves as an incubator for new biotech companies in the Southwest Michigan area. In 2010, CeeTox purchased certain assets formerly owned by ADMETRx Inc. This asset purchase increases CeeTox's existing ADME capabilities and is yet another step in its strategy to expand its range of in vitro service offerings. The scientists at CeeTox have a collective experience of more than 100 years in areas of cell culture, biochemistry, and toxicology. The team has analyzed more than 4,000 new chemical entities and has repeatedly demonstrated the value of early in vitro toxicity data in the drug discovery process. | Directeur des opérations | - |
Formation de Beth Allen
| Texas A&M University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Genomic Solutions, Inc.
Genomic Solutions, Inc. Packaged SoftwareTechnology Services Genomic Solutions, Inc. designs, develops genomic and proteomic instrumentation software solutions. It provides cell based assays, gene expression analysis, array hybridization, drug discovery and assay assembly. The company was founded by Jeffrey S. Williams in 1997 and is headquartered in Ann Arbor, MI. | Technology Services |
NextGen Sciences, Inc.
NextGen Sciences, Inc. BiotechnologyHealth Technology NextGen Sciences, Inc. specializes in the identification and characterization of proteins. The company is based in Ann Arbor, MI. NextGen Sciences was acquired by NextGen Group Plc on November 05, 2006 for $1.70 million. | Health Technology |
Lab Pathways, Inc.
Lab Pathways, Inc. Miscellaneous Commercial ServicesCommercial Services Lab Pathways, Inc. was founded in July of 2003 as a Contract Research Organization focused on in vitro toxicity screening of potential drug candidates and chemicals. CeeTox resides in 4,200-square-feet of state-of-the-art laboratory space in the Southwest Michigan Innovation Center (SMIC), a $13 million facility that serves as an incubator for new biotech companies in the Southwest Michigan area. In 2010, CeeTox purchased certain assets formerly owned by ADMETRx Inc. This asset purchase increases CeeTox's existing ADME capabilities and is yet another step in its strategy to expand its range of in vitro service offerings. The scientists at CeeTox have a collective experience of more than 100 years in areas of cell culture, biochemistry, and toxicology. The team has analyzed more than 4,000 new chemical entities and has repeatedly demonstrated the value of early in vitro toxicity data in the drug discovery process. | Commercial Services |